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ABSTRACT
Glucocorticoids (GC) are commonly used for the treatment of a wide variety of autoimmune, pulmonary, gastrointestinal, and
malignancy conditions. One of the devastating side effects of GC use is osteoporotic fractures, particularly in the spine and hip.
Bisphosphonates (BP) are the most commonly prescribed pharmacological agents for the prevention and treatment of GC-induced
osteoporosis (GIO). However, GIO is marked by reduced bone formation and BP serves mainly to decrease bone resorption. The WNT
signaling pathway plays a major role in bone and mineral homeostasis. Previously, we demonstrated that overexpression of WNT16
in mice led to higher bone mineral density and improved bone microarchitecture and strength. We hypothesized that WNT16
overexpression would prevent bone loss due to glucocorticoid treatment in mice. To test our hypothesis, we treated adult wild-type
and WNT16-transgenic mice with vehicle and GC (prednisolone; 2.1 mg/kg body weight) via slow-release pellets for 28 days. We
measured bone mass and microarchitecture by dual-energy X-ray absorptiometry (DXA) and micro-CT, and performed gene
expression and serum biochemical analysis. We found that GC treatment compared with the vehicle significantly decreased femoral
areal bone mineral density (aBMD), bone mineral content (BMC), and cortical bone area and thickness in both wild-type and
transgenic female mice. In contrast, the trabecular bone parameters at distal femur were not significantly changed by GC treatment
in male and female mice for both genotypes. Further, we observed significantly lower level of serum P1NP and a tendency of higher
level of serum TRAP in wild-type and transgenic mice due to GC treatment in both sexes. Gene expression analysis showed lower
mRNA levels of Wnt16, Opg, and Opg/Rankl ratio in GC-treated female mice for both genotypes compared with the sex-matched
vehicle-treated mice. These data suggest that although WNT16 overexpression resulted in higher baseline bone mineral density and
bone volume per trabecular volume (BV/TV) in the transgenic mice, this was insufficient to prevent bone loss in mice due to
glucocorticoid treatment. © 2018 The Authors JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone
and Mineral Research.
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Introduction
Glucocorticoids (GC) are commonly used in patients for thetreatment of a wide variety of autoimmune, pulmonary,
and gastrointestinal conditions, as well as in post-transplant and
malignancy treatments. An estimated 1.2% of individuals ages
20 to 80 years in the US receive prescriptions for GC, with 28% of
these patients using GC for more than 5 years.(1) GC is also used
frequently in other countries.(2) One of the most ignored and
devastating side effects of GC use is glucocorticoid-induced
osteoporosis (GIO), the most common form of secondary
osteoporosis.(1,3) GIO has a significant risk (30% to 50%) of
osteoporotic fractures, particularly in the hip and spine.(2) Thus,
GIO causes substantial morbidity and huge economic burden
worldwide.
Previous studies demonstrated that GC administration
has significant negative impact on skeletal health.(3–5) GC
decreases bone formation, increases bone resorption, as well as
increases bone cell death.(4,5) Thus, GC treatment rapidly
deteriorates bone mineral density (BMD) and strength, substan-
tially increasing fracture risk in patients. Importantly, this
fracture risk at a specific bone mineral density is greater for
patients taking GC than their non-GC counterparts; therefore,
treatment to prevent osteoporosis is even more vital in patients
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taking GC.(6) Currently, bisphosphonates (BP) are the most
commonly used pharmacological agents for the prevention and
treatment of GIO.(1,4) The benefits of BP are mostly attributable
to their antiresorptive effects; however, the primary hallmark of
GIO is reduced bone formation. Additionally, long-term BP
treatment has been associated with increased bone micro-
damage, osteonecrosis, and atypical fracture.(7,8) Parathyroid
hormone (PTH) therapy such as teriparatide (recombinant
human parathyroid hormone, analog 1-34) and abaloparatide
(an analog of human parathyroid related peptide, PTHrp 1-34)
enhance bone formation. However, both are contra-indicated in
children and patients with a history of skeletal malignancy or
Paget’s disease. Therefore, it is crucial to identify a different
approach leading to more bone formation, in addition to
prevention of bone loss, for the treatment of this condition.
The WNT (Wingless-type mouse mammary tumor virus
integration site) signaling pathway plays a major role in
embryonic development and postnatal health and disease,
including bone and mineral balance.(9) The WNT family is
composed of 19 secreted cysteine-rich glycoproteins, and
genomewide association studies demonstrated strong associ-
ations between WNT16 and both BMD and fracture risk across
multiple populations.(10,11) In addition, studies involving mice
revealed that WNT16 is a critical regulator for bone homeosta-
sis.(12,13) One of the mechanisms by which GC suppress bone
formation is through their effects on Wnt-signaling path-
way.(14,15) Recently, we created transgenic (TG) mice that
overexpress human WNT16 in bone tissue and demonstrated
that the TG mice displayed significantly higher bone mineral
density in whole body, hip, and spine starting as early as age
6 weeks in both males and females.(13) In addition, TG mice had
up to 13-fold higher bone volume at the inner trabecular bone
and significantly higher bone area and thickness at the outer
cortical bone, indicating that WNT16 overexpression in TG mice
also improved bonemicroarchitecture. Higher bone density and
superior bone quality in the TGmice led to higher bone strength
in these mice. Mechanistically, WNT16 overexpression increased
bone formation and reduced bone resorption in the TG mice.(13)
Furthermore, we detected significant reduction (55%) of Wnt16
mRNA expression in bone tissue in mice treated with GC.
Together, these results suggest that enhancing WNT16 expres-
sion in bone tissue might have great potential to improve bone
mass and strength in GIO. We hypothesized that WNT16
overexpression would prevent bone loss and prevent bone
fragility due to glucocorticoid treatment in mice. To test our
hypothesis, we treated adult wild-type and WNT16-transgenic
micewith vehicle andGC (prednisolone; 2.1mg/kg bodyweight)
via slow-release pellets for 28 days. Our data suggest that
althoughWNT16 overexpression in the transgenic mice resulted
in higher baseline and final bone mass and improved bone
microarchitecture, these mice still lost bone due to glucocorti-
coid treatment.
Materials and Methods
Generation of the Col2.3-hWNT16 transgenic mice
The generation of the Col2.3-hWNT16 transgenic mice was
described previously.(13) Briefly, the cDNA of human WNT16 was
cloned into the pJ251 plasmid between the osteoblast-specific
2.3 kb a1 type 1 collagen promoter and mouse protamine 1
polyA signal. The transgene expression construct (promoterþ
WNT16 cDNAþpolyA tail sequence) was microinjected into
pronuclei of B6 fertilized eggs, which were then transferred into
C57BL/6 (B6) foster mothers by the Indiana University
Institutional Transgenic Animal Facility. The integration of the
transgene(s) into the genome of founder mice was determined
by PCR using tail DNA.
Experimental animals
Weused 6male and6 femalemice per genotype (Col2.3-hWNT16
TG and wild-type littermates as controls) in this study unless
stated specifically otherwise. Adult transgenic and wild-type
control mice at 16 weeks of age were delivered placebo and
prednisolone (2.1mg/kg/d) (Innovative Research of America,
Sarasota, FL, USA) via slow-release pellets for 28 days under
isoflurane anesthesia. To provide pain relief, mice were injected
analgesic (Carprofen 10mg/kg) subcutaneously approximately 1
hour before the pellet implantation. Food and water consump-
tion, body condition and mobility, and pellet implantation sites
were monitored regularly. All mice were generated and
maintained at Indiana University. Mice were housed in polycar-
bonate cages in a vivariummaintained on a 12-hour light and 12-
hour dark cycle and were fed a regular diet and water ad libitum.
The procedures performed throughout the experiment were in
accordance with the ethical standards and guidelines of the
Indiana University Animal Care and Use committee (IACUC).
Euthanasia and specimen collection
Mice were euthanized at 28 days after pellet implantation. The
lower limbs (femur and tibia) and lumbar 3 through 5
vertebrae were dissected from these animals. The femora on
the right side were immediately stored at 80 °C in saline-
soaked gauze for subsequent biomechanical testing. The
femora on the left side were stripped of muscle, fixed in 10%
neutral buffer formalin for 48 hours before transferred to 70%
ethyl alcohol and stored at 4 °C for densitometry analyses. In
addition, after removing of muscle and periosteum, both ends
of the tibia and humeri were cut to flush out the marrow cavity
with PBS before transferring them to RNA later stabilization
reagent (Qiagen, Valencia, CA, USA). We also harvested muscles
(gastrocnemius and quadriceps) from both placebo and
prednisolone-treated wild-type and Col2.3-hWNT16 transgenic
mice, the wet weights of which were used for muscle weight
analysis.
Dual-energy X-ray absorptiometry (DXA)
The whole body, femur and lumbar vertebrae 1 through 5 of
both the placebo and prednisolone-treated wild-type and
Col2.3-hWNT16 transgenic mice were scanned at 28 days after
pellet implantation using DXA (PIXImus II mouse densitome-
ter; Lunar Corp., Madison, WI, USA) with ultra-high resolution
(0.18 0.18mm/pixel) as described previously.(13) The global
window for the whole body was defined as the whole body
image minus calvarium, mandible, and teeth. After completion
of the scan of each bone, mutually exclusive region of interest
(ROI) boxes were drawn around the bone from which femur
areal bone mineral density (aBMD; g/cm2) and bone mineral
content (BMC; g) measurements were obtained. In addition,
from the whole body scans, the percent fat (%) and total body
mass (g) were measured. The lean body mass (g) was
measured by subtracting the body fat mass from the total
body mass and fat mass was normalized by the lean
body mass.
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Micro-computed tomography (mCT) analysis
The femurs and lumbar 5 vertebrae of both placebo and
prednisolone-treated wild-type and Col2.3-hWNT16 transgenic
mice were scanned at 28 days after pellet implantation with a
high-resolution mCT scanner (vivaCT 40, Scanco Medical AG,
Bruttisellen, Switzerland) with an isotropic voxel size of 10.5mm3
as described previously.(13) In brief, from the scout-view, the
growth plate location was identified and trabecular bone
measurements consisting of 200 slices (2.1mm)were completed
from about 1mm below the growth plate. Lumbar 5 vertebrae
measurements included the vertebral body from the cephalad
to the caudal endplate excluding the cortical bone. For cortical
bone analysis, themid-femur of each bonewas determined from
the scout-view and a total of 60 slices (30 slices above and
30 slices below the mid-femur) were scanned with the same
setting as described previously.(13) Finally, 3D and 2D morpho-
metric evaluations were performed for the cortical and
trabecular bone from each scan, and bone volume (BV/TV)
and structural parameters (trabecular number [Tb.N], trabecular
thickness [Tb.Th], trabecular separation [Tb.Sp], cortical bone
area [B.Ar/T.Ar], cortical thickness [Ct.Th]) were determined. The
use of the nomenclature, symbols, and units were followed as
described in Bouxsein and colleagues.(16)
Biomechanical measurements
Three-point bending measurement of whole-bone strength of
femur of both placebo and prednisolone-treated wild-type and
Col2.3-hWNT16 transgenic mice at 28 days after pellet
implantation was performed using an electromechanical test
machine (TestResources, Shakopee, MN, USA) as described
previously.(13) In brief, the femurs were held in place by small
preload (<1N) and each bone was loaded to failure in
monotonic compression using a crosshead speed of 0.2mm/s,
during which force and displacement measurements were
collected every 0.02 s. From the force versus displacement
curves, stiffness (N/mm), ultimate force (N), energy to ultimate
force (mJ), and energy to failure (mJ) were calculated using
MTestWR software following standard equations.
Serum biomarkers
Serum levels of mouse pro-collagen 1 intact N-terminal (P1NP),
carboxy-terminal collagen cross-links (CTX) and tartrate-
resistant acid phosphatase 5, isoform b (TRAcP5b) of both
placebo and prednisolone-treated wild-type and Col2.3-
hWNT16 transgenic mice at 28 days after pellet implantation
were measured by ELISA kits (Immunodiagnostic Systems,
Scottsdale, AZ, USA, and Biomedical Technologies Inc.,
Stoughton, MA, USA) according to the manufacturers’ instruc-
tions. As our previous study(14) demonstrated, changes of serum
levels of P1NP occur as early as two weeks post-GC treatment,
we also measured this value at 2 weeks after pellet implantation
in GC-treated wild-type and transgenic mice. Serum calcium
(Ca), phosphorus (Phos), blood urea nitrogen (BUN), creatinine
(CREA), and alkaline phosphatase (ALP) were measured using
the Randox Rx kit (Daytona Analyzer, Randox Laboratories,
Charles Town, WV, USA).
Gene expression analysis
Measurements of gene expression were performed by real-time
PCR using bone tissue (femur) from both placebo and
prednisolone-treated wild-type and Col2.3-hWNT16 transgenic
mice at 28 days after pellet implantation as described
previously.(13) All qPCR reactions were performed using the
custom-made primer and probe sets from Integrated DNA
Technology (IDT, Coralville, IA, USA) or from Applied Biosystems
(Carlsbad, CA, USA) for human WNT16 (hWNT16), endogenous
mouse Wnt16 (Wnt16), runt-related transcription factor 2
(Runx2), alkaline phosphatase (Alp), osteocalcin (OC), osteopro-
tegerin (Opg), and tumor necrosis factor (ligand) superfamily,
member 11 (Rankl or Tnfs11). Real-time detection of PCR
products was accomplished using an ABI PRISM 7900 sequence
detector (Applied Biosystems) and normalized to the house-
keeping gene beta-Actin.
Statistical analysis
Quantitative data were expressed as mean SEM. Statistical
differences between placebo and prednisolone-treated groups
were tested in wild-type and Col2.3-hWNT16 transgenic mice
using the unpaired Student’s t test. In addition, a two-factor
ANOVA analysis was performed to identify the interaction
effects of GC treatment with genotype for all measured
parameters. All statistical analysis was performed using the
statistical software package StatView (Abacus Concepts, Inc.,
Berkeley, CA, USA). The level of significance was set at p  0.05.
Results
GC treatment significantly lowered the body weight in
both wild-type and Col2.3-hWNT16 TG mice
The baseline body weight demonstrated no significant differ-
ence between placebo and GC-treated male and female wild-
type and transgenic mice (Supplemental Table S1). The body
weight measured at 28 days after pellet implantation showed
that both male and female wild-type mice had significantly
lower body weight (p< 0.05 and p< 0.005, respectively) due to
GC treatment compared with the placebo-treated control mice
(Fig. 1A, B). The Col2.3-hWNT16 TG mice treated with GC also
displayed significantly lower body weight in both male
(p< 0.005) and female (p< 0.05) mice compared with the
placebo group (Fig. 1A, B).
Bone lengths are similar in GC-treated wild-type
and Col2.3-hWNT16 TG mice compared with the
placebo-treated mice in both male and female
Both male and female wild-type mice treated with placebo and
GC showed similar femur length at 28 days after pellet
implantation (Fig. 1A, B). In addition, bone length in Col2.3-
hWNT16 TG mice treated with placebo and GC did not differ in
both sexes, suggesting that GC has minimum effect on growth
of adult bone (Fig. 1A, B). Also, two-way ANOVA analysis
demonstrated no significant interaction effects of GC treatment
with genotype for bone length (Supplemental Table S2).
Areal BMD and BMC of whole body and spine are similar
in GC-treated wild-type and Col2.3-hWNT16 TG mice
compared with the placebo-treated mice in both male
and female
The baseline whole body and spine aBMD and BMC were similar
between placebo and GC-treated male and female wild-type
and transgenic mice (Supplemental Table S1). Male and
female Col2.3-hWNT16 TG mice treated with placebo had
significantly higher whole body aBMD (p< 0.006 and p< 0.0001,
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respectively) and BMC (p< 0.01 and p< 0.01, respectively)
compared with WT placebo group at 28 days after pellet
implantation (Supplemental Fig. S1A, B). GC treatment did not
change whole body aBMD significantly in male and female wild-
type and Col2.3-hWNT16 TG mice compared with placebo-
treatedmice. A slight but nonsignificant decrease of whole body
BMC was observed in GC-treated male and female mice in both
genotypes except male TG mice treated with GC displayed
significantly lower BMC compared with sex-matched placebo
group (Supplemental Fig. S1A, B). Male and female Col2.3-
hWNT16 TG mice treated with placebo had significantly higher
spine (L1–5) aBMD (p< 0.02 and p< 0.001, respectively) and BMC
(p< 0.02 and p< 0.01, respectively) compared with WT placebo
group (Supplemental Fig. S2A, B). GC treatment did not
significantly change spine aBMD and BMC in male and female
wild-type and Col2.3-hWNT16 TG mice compared with placebo-
treated mice (Supplemental Fig. S2A, B). Two-way ANOVA
analysis demonstrated no significant interaction effects of GC
treatment with genotype for whole body and spine aBMD and
BMC (Supplemental Table S2).
GC treatment significantly lowered femoral aBMD and
BMC in both wild-type and Col2.3-hWNT16 TG female
mice
The baseline femur aBMD and BMC showed no significant
difference between placebo and GC-treated male and female
wild-type and transgenic mice (Supplemental Table S1).
Male and female Col2.3-hWNT16 TG mice treated with placebo
had significantly higher femoral aBMD (p< 0.03 and p< 0.002,
respectively) and BMC (p¼ 0.01 and p< 0.01, respectively)
compared with WT placebo group at 28 days after pellet
implantation (Fig. 2A, B). Male wild-type mice treated with GC
had slightly but nonsignificantly lower femoral BMC compared
with the placebo-treated mice (Fig. 2A). Female wild-type mice
treated with GC had significantly lower femoral aBMD and
BMC (p< 0.05 and p< 0.05, respectively) compared with the
placebo-treated mice (Fig. 2B). Similarly, female Col2.3-
hWNT16 TG mice treated with GC had significantly lower
femoral aBMD and BMC (p< 0.05 and p< 0.05, respectively)
compared with the placebo-treated mice (Fig. 2B). Two-way
ANOVA analysis demonstrated no significant interaction
effects of GC treatment with genotype for femur aBMD and
BMC (Supplemental Table S2).These data suggest that over-
expression of WNT16, although increasing bone mass overall,
did not prevent bone loss due to GC treatment in the female
transgenic mice.
GC treatment did not change bone microarchitecture in
cancellous bone in distal femur measured by mCT
To further identify the effects of the GC treatment on skeletal
properties in wild-type and Col2.3-hWNT16 TG mice, we
measured bone microarchitectural properties in the distal
femur for cancellous bone using mCT. Both male and female
Col2.3-hWNT16 TG mice treated with placebo displayed
Fig. 1. Measurement of body weight and bone length. The body weight measured at 28 days after pellet implantation showed that both male (A) and
female (B) wild-typemice had significantly lower bodyweight due toGC treatment comparedwith the placebo-treated controlmice. The Col2.3-hWNT16
TGmice treated with GC also displayed significantly lower body weight in both male and female mice compared with the placebo group. Both male and
female wild-type mice treated with placebo and GC showed similar femur length at 28 days after pellet implantation. In addition, bone length in
Col2.3-hWNT16 TG mice treated with placebo and GC did not differ in both sexes. Values are given as mean SEM; p< 0.05 and p< 0.005 versus
genotype-matched placebo-treated mice using Student’s t test. GC¼glucocorticoid.
ALAM ET AL.4 of 14 -%05 3OXV :2$
significantly higher (p< 0.001) trabecular BV/TV, Tb.N, and Tb.Th
and significantly lower (p< 0.001) Tb.Sp compared with WT
placebo group at 28 days after pellet implantation (Fig. 3A, B). GC
treatment did not change trabecular BV/TV and Tb.Th in male
and female wild-type and Col2.3-hWNT16 TG mice compared
with genotype-matched placebo-treated mice (Fig. 3A, B). Both
GC- and placebo-treated wild-typemice displayed similar values
for Tb.N and Tb.Sp in male, whereas Tb.N was significantly
higher (p< 0.05) and Tb.Sp was significantly lower (p< 0.05) in
GC-treated male transgenic mice (Fig. 3A). Tb.N was also
significantly higher (p< 0.05) and Tb.Sp was significantly
lower (p< 0.05) in GC-treated female wild-type mice compared
with placebo-treated mice (Fig. 3B). Two-way ANOVA
analysis demonstrated no significant interaction effects of GC
treatment with genotype for all trabecular mCT measurements
(Supplemental Table S2).
GC treatment significantly compromised cortical bone
micro-architecture at femur midshaft measured by mCT
GC treatment did not change cortical BA/TA and Ct.Th in male
wild-type and Col2.3-hWNT16 TG mice compared with sex-
matched placebo-treated mice (Fig. 4A). In female mice, both
BA/TA and Ct.Thwere significantly lower in GC-treatedwild-type
(p< 0.005 and p< 0.05, respectively) and Col2.3-hWNT16
TG mice (p< 0.005 and p< 0.005, respectively) compared
with placebo-treated control mice (Fig. 4B). The polar moment
of inertia (pMOI) was also significantly lower in female
GC-treated wild-type and Col2.3-hWNT16 TG mice (p< 0.05
and p< 0.001, respectively) compared with genotype-matched
placebo-treated mice (Fig. 4B). Two-way ANOVA analysis
demonstrated no significant interaction effects of GC treatment
with genotype for all cortical mCTmeasurements (Supplemental
Table S2).
Biomechanical properties of femurs are compromised
due to GC treatment in wild-type and Col2.3-hWNT16
TG mice
To identify the effect on GC treatment in mechanical properties
of the skeleton in wild-type and Col2.3-hWNT16 mice, we
tested femurs from these mice using monotonic 3-point
bending tests. Female wild-type mice treated with GC had
significantly lower stiffness (p< 0.005), ultimate force
(p< 0.05), and energy to ultimate force (p< 0.05) compared
with sex-matched placebo-treated mice (Fig. 5B). Female
Col2.3-hWNT16 mice treated with GC also displayed signifi-
cantly lower stiffness (p< 0.05), ultimate force (p< 0.05),
energy to ultimate force (p< 0.05), and energy to failure
(p< 0.05) compared with placebo-treated Col2.3-hWNT16
control mice (Fig. 5B). In contrast, male wild-type mice treated
with GC had a trend for lower values and male Col2.3-hWNT16
mice treated with GC had similar values for these biomechani-
cal parameters compared with genotype-matched placebo-
treated mice (Fig. 5A). Two-way ANOVA analysis demonstrated
no significant interaction effects of GC treatment with
genotype for all femur biomechanical parameters (Supplemen-
tal Table S2).
Fig. 2. Femur aBMD and BMC measured by DXA. Male (A) and female (B) Col2.3-hWNT16 TG mice treated with placebo had significantly higher
femoral aBMD and BMC compared with WT placebo group at 28 days after pellet implantation. Female wild-type mice treated with GC had significantly
lower femoral aBMD and BMC compared with the placebo-treated mice. Similarly, female Col2.3-hWNT16 TG mice treated with GC had significantly
lower femoral aBMD and BMC compared with the placebo-treated mice. Values are given as mean SEM; p< 0.05 and p< 0.005 versus genotype-
matched placebo-treated mice using Student’s t test. GC¼glucocorticoid.
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Fig. 3. Trabecular bone morphometry measured by micro-CT. Both male (A) and female (B) Col2.3-hWNT16 TG mice treated with placebo displayed
significantly higher trabecular BV/TV, Tb.N, Tb.Th, and significantly lower Tb.Sp comparedwithWT placebo group at 28 days after pellet implantation. GC
treatment did not change trabecular BV/TV and Tb.Th in male and female wild-type and Col2.3-hWNT16 TG mice compared with placebo-treated mice.
Tb.N and Tb.Sp were also similar in GC and placebo-treated male wild-type mice and female transgenic mice, whereas Tb.N was higher in GC-treated
male and female mice compared with placebo-treated mice. Tb.Sp was lower in GC-treated male Col2.3-hWNT16 TG mice and female wild-type mice
compared with genotype-matched placebo-treated mice. Values are given as mean SEM; p< 0.05 versus genotype-matched placebo-treated mice
using Student’s t test. GC¼glucocorticoid.
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Fig. 4. Cortical bone morphometry measured by micro-CT. Both male (A) and female (B) Col2.3-hWNT16 TG mice treated with placebo displayed
significantly higher cortical bone area (BA/TA) and thickness (Ct.Th) compared withWT placebo group at 28 days after pellet implantation. GC treatment
did not change trabecular BA/TA and Ct.Th in male wild-type and Col2.3-hWNT16 TG mice compared with placebo-treated mice. Both BA/TA and Ct.Th
were significantly lower in GC-treated wild-type and Col2.3-hWNT16 TGmice in female compared with placebo-treated control mice. The polar moment
of inertia (pMOI) was also significantly lower in female GC-treated wild-type and Col2.3-hWNT16 TG mice compared with genotype-matched placebo-
treatedmice. Values are given as mean SEM; p< 0.05, p< 0.005, and p< 0.0001 versus genotype-matched placebo-treatedmice using Student’s
t test. GC¼glucocorticoid.
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Serum markers of bone formation are significantly
influenced in both wild-type and Col2.3-hWNT16 TG
mice due to GC treatment
To understand potential changes in serum biochemistry induced
by GC treatment in wild-type and Col2.3-hWNT16 mice, we
measured biomarkers related to skeletal metabolism in serum
samples. At 2 weeks after pellet implantation, both wild-type and
Col2.3-hWNT16 male mice showed significantly lower levels of
serum P1NP (p< 0.005 and p< 0.001, respectively), a bone
formationmarker, due toGC treatment comparedwith genotype-
matched placebo-treated mice (Fig. 6A). Similarly, female
Fig. 5. Measurement of bone strength by femur biomechanical test. Female (B) wild-type and Col2.3-hWNT16mice treatedwith GC had significantly lower
stiffness, ultimate force, energy to ultimate force, and energy to failure compared with placebo-treatedmice for both genotypes. In contrast, male (A) wild-
type and Col2.3-hWNT16mice treated with GC had similar values for these biomechanical parameters compared with genotype-matched placebo-treated
mice. Values are givenasmean SEM; p< 0.05and p< 0.005versusgenotype-matchedplacebo-treatedmiceusingStudent’s t test. GC¼glucocorticoid.
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GC-treated wild-type and transgenic mice also showed signifi-
cantly lower levels of serum P1NP (p< 0.05 and p< 0.001,
respectively) compared with genotype-matched placebo-treated
mice (Fig. 6A). However, the serum level of P1NP was re-
established to the baseline level at 4 weeks post-treatment (data
not shown). At 28 days after pellet implantation, serum levels of
CTXandTRAPweresimilar inGC-treatedwild-typemice compared
with placebo-treated mice in both male and female (Fig. 6B). A
slightly higher but nonsignificant level of CTX was observed in
GC-treated Col2.3-hWNT16mice comparedwith placebogroup in
both sexes (Fig. 6B). In addition, significantly higher (p< 0.05) level
of TRAP in male and a slightly higher but nonsignificant level of
TRAP were observed in female GC-treated Col2.3-hWNT16 mice
compared with placebo group (Fig. 6B). Also, similar levels of
calcium, phosphorus, and creatinine were detected in GC-treated
wild-type and Col2.3-hWNT16mice compared with their placebo-
treated WT littermates in both male and female (Table 1).
Lean body mass is significantly decreased in both
wild-type and Col2.3-hWNT16 TG mice due to GC
treatment
We measured lean body mass and fat mass normalized by the
lean body mass derived from DXA collected at 28 days after
pellet implantation. Wild-type mice treated with GC showed
significantly lower lean body mass in male (p< 0.05) and female
(p< 0.005) compared with the placebo-treated mice (Fig. 7A, B).
Similarly, Col2.3-hWNT16 mice treated with GC showed
significantly lower lean body mass in male (p< 0.05) and female
(p< 0.005) compared with their placebo-treated mice (Fig. 7A,
B). Both wild-type and Col2.3-hWNT16 mice treated with GC
showed similar fat mass values compared with their genotype-
matched placebo groups in male and female (Fig. 7A, B).
Two-way ANOVA analysis demonstrated no significant interac-
tion effects of GC treatment with genotype for lean body and fat
mass (Supplemental Table S2).
Muscle mass is significantly influenced in both wild-type
and Col2.3-hWNT16 TG male mice due to GC treatment
Wild-type mice treated with GC showed significantly lower
gastrocnemius (p< 0.005) and quadriceps (p< 0.05) musclemass
in male compared with the sex-matched placebo-treated mice
(Fig. 8A). Col2.3-hWNT16 male mice treated with GC also showed
significantly lower gastrocnemius (p< 0.05) and quadriceps
(p< 0.05) muscle mass compared with their placebo-treated
mice (Fig. 8A). In addition, a trend of lower gastrocnemius and
quadriceps muscle mass in both WT and Col2.3-hWNT16
Fig. 6. Analyses of serum bone formation and resorption markers. Both wild-type and Col2.3-hWNT16 mice showed significantly lower levels of serum
P1NP at 2 weeks after pellet implantation due to GC treatment compared with genotype-matched placebo-treated mice. Serum levels of CTX and TRAP
were similar in GC-treated wild-typemice compared with placebo-treatedmice in both male (A) and female (B) mice at 28 days after pellet implantation.
A slightly higher but nonsignificant level of CTX and TRAP were observed in GC-treated Col2.3-hWNT16 mice compared with placebo group in both
sexes. Values are given as mean SEM; p< 0.05, p< 0.005, and p< 0.0001versus genotype-matched placebo-treated mice using Student’s t test.
GC¼glucocorticoid.
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GC-treatedmice comparedwith their genotype-matchedplacebo
groups in female (Fig. 8B) was found. Two-way ANOVA analysis
demonstrated no significant interaction effects of GC treatment
with genotype for muscle mass (Supplemental Table S2).
Expression of bone formation and resorption related
genes are changed in both wild-type and
Col2.3-hWNT16 TG mice due to GC treatment
We detected a trend of lower levels of hWNT16 expression in
bone tissue (femur) in Col2.3-hWNT16 mice treated with GC
compared with placebo-treated mice (Fig. 9). In addition, the
level of endogenous mouse Wnt16 mRNA expression was
slightly but nonsignificantly lower in both wild-type and Col2.3-
hWNT16 mice treated with GC compared with their genotype-
matched placebo groups (Fig. 9). A trend of lower mRNA levels
of Alp in wild-type and Runx2 in both wild-type and Col2.3-
hWNT16 mice were observed treated with GC compared with
their genotype-matched placebo groups (Fig. 9). The levels of
osteocalcin and Trap mRNA expressions were similar in both
placebo- and GC-treated mice for both genotypes (Fig. 9).
Table 1. Serum Biochemistry in Male and Female Wild-Type and Col2.3-hWNT16 Transgenic Mice Treated With Placebo and GC
Male (WT) Male (TG) Female (WT) Female (TG)
Ca (mg/dL)
Placebo 9.1 0.2 8.7 0.2 9.2 0.1 9.2 0.1
GC 9.5 0.3 9.2 0.1 9.2 0.2 9.1 0.2
p value 0.25 0.10 0.84 0.82
Phos (mg/dL)
Placebo 8.1 0.6 7.9 0.6 10.1 1.2 8.7 0.7
GC 9.2 0.4 6.7 0.6 9.6 1.3 8.8 0.9
p value 0.10 0.11 0.79 0.97
CREA (mg/dL)
Placebo 0.37 0.02 0.36 0.02 0.41 0.02 0.40 0.01
GC 0.40 0.02 0.38 0.03 0.40 0.02 0.39 0.02
p value 0.09 0.50 0.60 0.77
WT¼wild type; TG¼Col2.3-hWNT16 transgenic; GC¼glucocorticoid; Ca¼ calcium; Phos¼phosphorus; CREA¼ creatinine.
Values are mean SEM.
Fig. 7. Lean body and fat massmeasured by DXA. The lean bodymass derived fromDXA collected at 28 days after pellet implantation showed that both
wild-type and Col2.3-hWNT16mice treated with GC had significantly lower lean bodymass inmale (A) and female (B) mice compared with their placebo-
treated WT littermates. In addition, both wild-type and Col2.3-hWNT16 mice treated with GC displayed similar fat mass values normalized by the lean
body mass compared with their genotype-matched placebo groups in male and female. Values are given as mean SEM; p< 0.05 and p< 0.005
versus genotype-matched placebo-treated mice using Student’s t test. GC¼glucocorticoid.
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Further, a higher but nonsignificant level of Pparg mRNA
expression was observed in both placebo- and GC-treated mice
for both genotypes (Fig. 9). In addition, trends of lower
expression of Opg and Opg/Rankl ratio were detected in the
GC-treated wild-type and transgenic mice compared with their
genotype-matched placebo groups (Fig. 9).
Discussion
Our data demonstrate that GC had significant detrimental effect
on lean body mass and muscle mass in both male and female
wild-type and Col2.3-hWNT16 transgenic mice. GC treatment
also significantly lowered the femoral aBMD and BMC in female
mice for both genotypes. Micro-CT analysis revealed that GC
significantly decreased cortical bone area and thickness in
female mice, which correlated with the reduction of bone
strength in these mice for both genotypes. In contrast, the
trabecular bone parameters in femur and spine were not
significantly changed by GC treatment in male and female
wild-type and Col2.3-hWNT16 transgenic mice. Serum biomark-
ers showed that P1NP levels were significantly reduced in both
male and female wild-type and transgenic mice. We also
observed a trend of lower mWnt16, Runx2, Opg, and Opg/Rankl
ratio in GC-treated mice for both genotypes. Together
these results suggest that although overexpression of WNT16
increased bone mass significantly in both vehicle and
GC-treated mice, it did not completely prevent bone loss in
mice due to glucocorticoid treatment.
In this study, we observed sex- and site-specific influence of
GC on bone density and mineral content due to glucocorticoid
treatment. Although whole body and lumbar spine aBMD and
BMC were not significantly changed due to GC treatment in
male and female wild-type and Col2.3-hWNT16 transgenic mice
(Supplemental Figs. S1 and S2), GC-treated female mice showed
significantly lowered aBMD and BMC in femur for both
genotypes compared with placebo-treated mice (Fig. 2B).
Male wild-type and transgenic mice treated with GC had slightly
but nonsignificantly lower femoral BMC compared with the
placebo-treated mice (Fig. 2A). Previously, several studies
demonstrated that GC influence both cortical and trabecular
bone density and microarchitecture involving both axial and
appendicular skeletons.(14,17–19) Although some studies found
lower cortical and trabecular bone density due to GC
treatment,(17–19) other studies showed trabecular bone volume
over tissue volume was not significantly changed or even
increased.(14,20) Most of these studies demonstrated that cortical
bone volume and thickness were significantly lowered by GC
treatment.(14,18,19) Consistent with these studies, we also
discovered femur cortical bone area and thickness were
significantly decreased due to GC treatment in both wild-type
and transgenic mice (Fig. 4B). In contrast, trabecular
bone microarchitecture parameters were not changed due to
GC treatment in both distal femur and spine. These could be
attributable to the different doses and duration of the GC used
as well as genetic backgrounds of mice employed in different
studies. Importantly, the predominant cortical effect in female
mice for both genotypes led to significantly lowered bone
biomechanical parameters due to GC treatment (Fig. 5B).
Previous studies demonstrated that administration of GC led
to initial increase in biochemical markers of bone resorption
Fig. 8. Measurement of muscle mass. Both wild-type and Col2.3-hWNT16 mice treated with GC showed significantly lower gastrocnemius and
quadriceps muscle mass in male (A) compared with their placebo-treated WT littermates. In addition, a trend of lower gastrocnemius and quadriceps
muscle mass in WT and Col2.3-hWNT16 GC-treated mice compared with their genotype-matched placebo groups in female (B). Values are given as
mean SEM; p< 0.05 and p< 0.005 versus genotype-matched placebo-treated mice using Student’s t test. GC¼glucocorticoid.
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followed by a suppression of both bone formation and
resorption markers.(3,4) Significantly lower serum levels of
P1NP (Fig. 6) in GC-treated wild-type and transgenic mice as
early as 2 weeks post-treatment in the current study suggest
that the detrimental effect of GC on bone formation could be a
major factor for decreased bone mineral density and strength in
these mice, and higher level of WNT16 expression in the
transgenic mice offers limited protection to the negative effects
on bone formation. In addition, the serum level of P1NP was
re-established to the baseline level at 4 weeks post-treatment
(data not shown), suggesting that suppression of bone
formation marker is temporary. Although serum levels of CTX
and TRAcP5b did not change significantly between placebo and
GC treatment in the wild-type mice in both male and female, a
trend of higher levels of CTX and TRAcP5b were observed in the
GC-treated transgenic mice in both sexes (Fig. 6), suggesting
higher WNT16 expression in the transgenic mice offers no
protection on bone resorption. GC treatment might prolong
osteoclast survival in the transgenic mice, which is evident by
higher TRAP level in this genotype.
Although GC affects both bone formation and resorption, the
major or primary effect is the decrease of bone formation due to
the direct effect of GC on cells of the osteoblastic lineage.(5,21–23)
GC decreases the proliferation of osteoblast as well as impairs
osteoblastic differentiation and function.(5,21) This is due to
inhibition of key regulators of osteoblastogenesis or repression
of genes important in osteoblast differentiation. In addition, GC
redirects the stromal cells toward cells of other lineages such as
adipocyte as well as increases early death of osteoblasts by
increasing the activation of apoptotic genes.(21) In this study, we
observed a trend of lower expression of Alp, Runx2, Opg, and
Opg/Rankl ratio and higher expression of Pparg in the
GC-treated wild-type and transgenic mice compared with their
genotype-matched placebo groups (Fig. 9). In addition,
endogenous mouse Wnt16 mRNA expression was lower and a
trend of lower levels of hWNT16 expression in GC-treated mice
for both genotypes. Decreased expression of bone formation
genes and inhibition of Wnt-signaling pathway that is critical for
bone formation and differentiation along with limited protec-
tion on bone formation due to higher hWNT16 expression all
together had a tremendous negative role on skeletal homeo-
stasis in GC-treated mice.
Previously, several approaches were undertaken to prevent
GC-induced bone loss using different interventions. For
Fig. 9. Analyses of gene expression in the bone tissue. A trend of lower levels of hWNT16 expression was detected in bone tissue (femur) in Col2.3-
hWNT16 mice treated with GC compared with placebo-treated mice. In addition, the level of endogenous mouseWnt16mRNA expression was lower in
both wild-type and Col2.3-hWNT16 mice treated with GC compared with their genotype-matched placebo groups. A trend of lower mRNA levels of Alp
and Runx2 were observed in both wild-type and Col2.3-hWNT16 mice treated with GC compared with their genotype-matched placebo groups. The
levels of osteocalcin, trap, and ctskmRNA expressions were similar. In addition, a trend of lower expression of Opg and Opg/Rankl ratio were detected in
the GC-treated wild-type and transgenic mice compared with their genotype-matched placebo groups.
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example, therapies involving intermittent PTH,(22,24) sost-anti-
body,(18) anti-Rankl antibody,(19) IL-6 neutralizing antibody,(25) as
well as inhibition of HSP90(26) and endoplasmic reticulum
stress(23) prevented the bone phenotypes due to GC treatment
to variable degrees in vivo. Moreover, genetic approaches using
knockout mice of mitogen-activated protein kinase phospha-
tase 1,(27) plasminogen activator inhibitor 1,(28) Npy,(29) sost,(14)
and autophagy-related gene 7(30) have been used to prevent
GC-induced bone loss but resulted in variable outcomes. Our
transgenic (TG) mice that overexpress human WNT16 in bone
tissue displayed significantly higher bone mineral density in
whole body, hip, and spine.(13) They also showed significantly
higher trabecular bone volume and cortical bone area and
thickness as well as higher bone strength. WNT16 over-
expression had a dramatic positive influence on bone formation
but minimum effect on bone resorption. Because one of the
main effects of GC is the decrease of bone formation due to the
direct effect on cells of the osteoblastic lineage, WNT16
overexpression could have the potential to prevent bone loss
and prevent bone fragility due to glucocorticoid treatment in
mice. However, our data in the current study shows that WNT16
overexpression in the transgenic mice does not prevent bone
loss. It should be noted thatWNT16-TGmice treatedwith GC had
higher BMD and strength than WT mice. Previous studies
demonstrated that GC-mediated bone loss involves Wnt-
signaling pathway, particularly Wnt-antagonists such as Sost
and Dkk1.(14,15,18) Ohnaka and colleagues showed that GC
suppressedWnt3a in cultured human osteoblasts;(31) however, it
is yet to be determined whether any specific Wnt molecule/s
play a critical role in this process in vivo. Our current study
demonstrates that GC-induced loss of bone might be less
dependent on the Wnt16-signaling pathway and mainly
regulated by other molecules/factors.
GC-induced myopathy was observed in other animal studies
and in patients,(2,14,32) which involves proteolysis of muscle
fibers due to activation of lysosomal and ubiquitin-proteasome
enzymes or by upregulation of myostatin, a negative regulator
of muscle mass. We also observed that GC had a significant
detrimental effect on lean body mass and muscle mass in both
male and female wild-type and Col2.3-hWNT16 transgenic mice
(Fig. 8), suggesting higher WNT16 expression in the transgenic
mice offers no protection on muscle loss. These results also
suggest that loss of muscle mass might be independent on the
Wnt16-signaling pathway and predominantly regulated by
other factors.
The dose of glucocorticoid (2.1mg/kg body weight) selected
in this study had been previously shown to produce glucocorti-
coid-induced osteoporosis in mouse model.(5,14) This dose is
approximately two to three times higher than the high
therapeutic dose (40 to 60mg/d in 60 kg individual) used in
human. The dose necessary to produce a similar effect to
clinically used dose in humans is consistently higher in mice due
to higher metabolic rate and higher clearance than in humans.
Also, we used adult mice to avoid the difference on bone
phenotypes during the growth period. The duration of 28 days is
equivalent to approximately 2 years in humans, representing
long-term effects or chronic GC administration to humans.
Some of the limitations of our studies include: 1) we used 6
animals per group; 2) we tested only one dose of GC; 3) we did
not investigate gene expression studies in male mice; 4) we
did not analyze bone histomorphometry; and 5) we did not
investigate thoroughly the mechanism of muscle loss in our
mouse model.
In conclusion, we demonstrated that GC had a significant
detrimental effect on lean body mass and muscle mass in both
male and female wild-type and WNT16-transgenic mice. GC
treatment also significantly lowered the femoral aBMD and BMC,
cortical bone area and thickness, and reduction of bone strength
in femalemice. Serum biomarkers showed that P1NP levels were
significantly reduced in both male and female wild-type and
WNT16-transgenic mice. We also observed a trend of lower
Runx2, Opg, and Opg/Rankl ratio in GC-treated mice for both
genotypes. Together these results suggest that overexpression
of WNT16 was insufficient to prevent bone loss in mice due to
glucocorticoid treatment, although WNT16-TG mice treated
with GC had higher BMD and strength than WT mice.
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